Keeping Up With Developments in NASH

Addressing Gaps In the Continuum of Care

Attend in person

Thank you for signing up

You will receive a reminder email the day before the event.

Register Now

Monday, October 23, 2017

Marriott Marquis Washington, DC

Marquis Ballroom Salon 6 - 10 Meeting Level 2

Washington, DC


Maximum Of 1.5 AMA PRA Category 1 Credit(s)


In this symposium, participants will have unique opportunities to interact with leading experts on the practical challenges of diagnosis, treatment, and management of nonalcoholic steatohepatitis (NASH), a growing epidemic in the United States and the most common form of chronic liver disease worldwide. Highlights of the symposium will include the current status of emerging therapies and how they may fit into the multidisciplinary approach to the management of patients with NASH.


Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri

Manal F. Abdelmalek, MD, MPH

Associate Professor of Medicine, NAFLD Clinical Research Program, Division of Gastroenterology/Hepatology, Duke Univeristy, Durham, North Carolina

Kenneth Cusi, MD

Professor of Medicine; Chief, Division of Endocrinology, Diabetes, and Metabolism, The University of Florida, Gainesville, Florida



Monday, October 23, 2017

6:30pm - 7:00pm


7:00pm - 8:30pm


Welcome and Introduction

Brent A. Neuschwander-Tetri, MD

NASH Is on the Spectrum

Brent A. Neuschwander-Tetri, MD

NASH: The Growing Epidemic

Kenneth Cusi, MD

Diagnostic Challenges

Manal F. Abdelmalek, MD, MPH


Kenneth Cusi, MD


Manal F. Abdelmalek, MD, MPH

Concluding Remarks

Brent Neuschwander-Tetri, MD

Question and Answer Session


Target Audience

This activity is intended for hepatologists, gastroenterologists, diabetologists, endocrinologists, and primary care physicians.

Goal Statement

The goal of this activity is to increase participants' competence in the evaluation, diagnosis, and treatment of patients with nonalcoholic steatohepatitis (NASH).

Learning Objectives

Upon completion of this activity, participants will

  • Have increased knowledge regarding the:
    • Targets of emerging therapies for NASH
    • The safety and efficacy of emerging therapies for NASH
  • Have greater competence related to
    • The role of noninvasive assessment in the evaluation of patients with NASH
    • The role of liver biopsy in the diagnosis of NASH

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credits Available:
Maximum Of 1.5 AMA PRA Category 1 Credit(s)

Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Association Disclosure Statement

Presented for attendees of the 68th AASLD Annual Meeting. This event/function is sponsored by Medscape Education and supported by Intercept Pharmaceuticals, Inc. This is not an official function/event of the American Association for the Study of Liver Diseases.


Marriott Marquis Washington, DC

Marquis Ballroom Salon 6 - 10 Meeting Level 2

901 Massachusetts Ave NW, Washington, DC 20001



Supported by independent educational grant from: